July 2, 2019

Novocure to Report Second Quarter 2019 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended… Read More
learn more
July 2, 2019

Novocure to Report Second Quarter 2019 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2019 on Thursday, July 25, 2019, before the U.S. financial markets open. Novocure management will host a conference call and webcast to discuss its financial results for the three months ended… Read More
learn more
June 26, 2019

German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma

National reimbursement decision for Optune® in Germany anticipated in 2020 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s EF-14 phase 3… Read More
learn more
June 26, 2019

German Institute for Quality and Efficiency in Healthcare Publishes Rapid Report Noting Optune’s Survival Benefit for Patients with Newly Diagnosed Glioblastoma

National reimbursement decision for Optune® in Germany anticipated in 2020 ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced that the German Institute for Quality and Efficiency in Healthcare, or IQWiG, has published its rapid report concluding that, based on a review of Novocure’s EF-14 phase 3… Read More
learn more
May 24, 2019

Novocure to Participate in the Jefferies 2019 Global Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle’s presentation will begin at 9 a.m. EDT and will be followed by a… Read More
learn more
May 24, 2019

Novocure to Participate in the Jefferies 2019 Global Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City. Mr. Doyle’s presentation will begin at 9 a.m. EDT and will be followed by a… Read More
learn more
May 23, 2019

FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In the STELLAR trial, malignant pleural mesothelioma patients treated with Tumor Treating Fields plus platinum-based chemotherapy experienced a median overall survival of 18.2 months ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure… Read More
learn more
May 23, 2019

FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

NovoTTF-100L, a Tumor Treating Fields delivery system, is the first FDA-approved mesothelioma treatment in more than 15 years In the STELLAR trial, malignant pleural mesothelioma patients treated with Tumor Treating Fields plus platinum-based chemotherapy experienced a median overall survival of 18.2 months ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure… Read More
learn more
May 10, 2019

Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to… Read More
learn more
May 10, 2019

Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma

ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM). Proposed LCDs are subject to… Read More
learn more